Janet E Brown

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9555892/publications.pdf

Version: 2024-02-01

65 papers	5,569 citations	136950 32 h-index	128289 60 g-index
70 all docs	70 docs citations	70 times ranked	5542 citing authors

#	Article	IF	Citations
1	Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 2022, 126, 419-429.	6.4	10
2	Identification of new therapeutic targets of bone cancers by proteomic strategies. , 2022, , 783-803.		0
3	Treatment Strategies in Metastatic Renal Cancer: Dose Titration in Clear Cell Renal Cell Carcinoma. European Urology, 2022, 82, 293-294.	1.9	1
4	Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, 2021, 20, 589-601.	4.1	16
5	The development of a theory and evidence-based intervention to aid implementation of exercise into the prostate cancer care pathway with a focus on healthcare professional behaviour, the STAMINA trial. BMC Health Services Research, 2021, 21, 273.	2.2	8
6	Towards implementing exercise into the prostate cancer care pathway: development of a theory and evidence-based intervention to train community-based exercise professionals to support change in patient exercise behaviour (The STAMINA trial). BMC Health Services Research, 2021, 21, 264.	2.2	6
7	Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care: a feasibility and acceptability study (the STAMINA trial). Scientific Reports, 2021, 11, 12470.	3.3	3
8	Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. Journal of Bone Oncology, 2021, 28, 100367.	2.4	4
9	Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. Diagnostics, 2021, 11, 1302.	2.6	3
10	Myeloma Bone Disease: The Osteoblast in the Spotlight. Journal of Clinical Medicine, 2021, 10, 3973.	2.4	7
11	Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. European Urology Focus, 2020, 6, 991-998.	3.1	23
12	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 2020, 6, 999-1005.	3.1	5
13	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 2020, 38, 4064-4075.	1.6	78
14	Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers, 2020, 12, 2109.	3.7	23
15	Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 2020, 25, 100311.	2.4	27
16	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptorâ€“Positive Metastatic Breast Cancer. JAMA Oncology, 2019, 5, 1556.	7.1	62
17	Dedicator of Cytokinesis 4: A Potential Prognostic and Predictive Biomarker Within the Metastatic Spread of Breast Cancer to Bone. Cancer Informatics, 2019, 18, 117693511986684.	1.9	5
18	Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research, 2019, 25, 2769-2782.	7.0	120

#	Article	IF	Citations
19	Bone Metastases; Clinical Aspects. , 2019, , 310-319.		3
20	Setting Research Priorities in Partnership with Patients to Provide Patient-centred Urological Cancer Care. European Urology, 2019, 75, 891-893.	1.9	12
21	Bone Health in Men with Prostate Cancer: Review Article. Current Osteoporosis Reports, 2019, 17, 527-537.	3.6	28
22	Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. Journal of Pathology, 2019, 247, 381-391.	4.5	33
23	Metastatic bone disease: Pathogenesis and therapeutic options. Journal of Bone Oncology, 2019, 15, 100205.	2.4	153
24	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 2019, 23, 1-328.	2.8	35
25	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. Journal of the National Cancer Institute, 2018, 110, 871-879.	6.3	32
26	Cancer Treatment and Bone Health. Calcified Tissue International, 2018, 102, 251-264.	3.1	60
27	Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Research, 2018, 78, 5300-5314.	0.9	22
28	A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS. PLoS ONE, 2018, 13, e0197606.	2.5	19
29	Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems. BMC Cancer, 2018, 18, 667.	2.6	4
30	Novel mediators of breast cancer bone metastasisâ€"insights from studies of gene-regulation and the global proteome. Annals of Translational Medicine, 2018, 6, S71-S71.	1.7	0
31	Bone-Targeted Therapies in Prostate Cancer. , 2017, , 343-356.		1
32	The role of biomarkers in the management of bone-homing malignancies. Journal of Bone Oncology, 2017, 9, 1-9.	2.4	71
33	The value of biomarkers in bone metastasis. European Journal of Cancer Care, 2017, 26, e12725.	1.5	39
34	Complications of bone metastases from malignant melanoma. Journal of Bone Oncology, 2017, 8, 13-17.	2.4	29
35	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clinical Cancer Research, 2016, 22, 5713-5721.	7.0	37
36	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2016, 2, 493.	7.1	78

#	Article	IF	Citations
37	CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 2016, 108, .	6.3	75
38	Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive Care in Cancer, 2016, 24, 1327-1337.	2.2	61
39	Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocrine-Related Cancer, 2014, 21, 327-341.	3.1	89
40	Assessment of the Impact of Targeted Therapy on Metastatic Bone Disease in Renal Cancer. European Urology, 2014, 66, 510-511.	1.9	0
41	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic featuresâ€"An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2013, 2, 70-76.	2.4	34
42	Osteonecrosis of the Jaw and Oral Healthâ€"Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04). Journal of Clinical Oncology, 2013, 31, 2685-2691.	1.6	41
43	Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers. Clinical Advances in Hematology and Oncology, 2013, 11, 281-7.	0.3	7
44	Denosumab in patients with cancerâ€"a surgical strike against the osteoclast. Nature Reviews Clinical Oncology, 2012, 9, 110-118.	27.6	81
45	Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients. Clinical Cancer Research, 2012, 18, 6348-6355.	7.0	76
46	Skeletal metastasis in renal cell carcinoma: Current and future management options. Cancer Treatment Reviews, 2012, 38, 284-291.	7.7	69
47	Skeletal complications and survival in renal cancer patients with bone metastases. Bone, 2011, 48, 160-166.	2.9	152
48	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, The, 2011, 377, 813-822.	13.7	1,748
49	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	4.4	84
50	Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?. Breast Cancer Research and Treatment, 2010, 123, 805-814.	2.5	62
51	Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 2010, 123, 767-779.	2.5	62
52	OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER ON LONGâ€TERM ANDROGEN DEPRIVATION THERAPY: AN INCREASING, BUT UNDERâ€RECOGNIZED PROBLEM. BJU International, 2010, 105, 1042-1043.	2.5	16
53	Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer. Neoplasia, 2010, 12, 685-696.	5.3	43
54	Biomarkers of bone turnover in oncology: applications in diagnosis and treatment. Expert Opinion on Medical Diagnostics, 2010, 4, 125-138.	1.6	5

#	Article	IF	Citations
55	Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer, 2008, 113, 193-201.	4.1	243
56	Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treatment Reviews, 2008, 34, 629-639.	7.7	108
57	Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clinical Cancer Research, 2008, 14, 6336-6342.	7.0	171
58	Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid. Clinical Cancer Research, 2007, 13, 5406-5410.	7.0	68
59	Effect of Chemotherapy on Skeletal Health in Male Survivors from Testicular Cancer and Lymphoma. Clinical Cancer Research, 2006, 12, 6480-6486.	7.0	26
60	Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid. Journal of Clinical Oncology, 2005, 23, 4925-4935.	1.6	493
61	Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors. Journal of the National Cancer Institute, 2005, 97, 59-69.	6.3	522
62	The role of bisphosphonates in breast and prostate cancers.. Endocrine-Related Cancer, 2004, 11, 207-224.	3.1	109
63	Metastatic Bone Disease. American Journal of Cancer, 2003, 2, 269-281.	0.4	17
64	Assessment of the effects of breast cancer on bone and the response to therapy. Breast, 2002, 11, 375-385.	2.2	16
65	The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Research, 2001, 4, 24-9.	5.0	34